Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
ObjectiveThe histological conversion of lung adenocarcinoma (LUAD) into small-cell lung cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment for SCLC p...
Main Authors: | Jianghua Ding, Zhaohui Leng, Hong Gu, Xiang Jing, Yun Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1153131/full |
Similar Items
-
Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study
by: Hatim Karachiwala, et al.
Published: (2021-01-01) -
Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
by: Pengbo Deng, et al.
Published: (2022-10-01) -
Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01) -
Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01) -
Bioinformatics-based screening of key genes for transformation of tyrosine kinase inhibitor-resistant lung adenocarcinoma to small cell lung cancer
by: Ying Zhang, et al.
Published: (2023-07-01)